Non-small-cell Lung Carcinoma
Conditions
Keywords
Non-small-cell lung carcinoma, Circulating tumor cells
Brief summary
The purpose of this study is to assess the value of circulating tumor cells (CTC)for non-small cell lung cancer in the postoperative recurrence monitoring by comparing the CTCs, CT and tumor markers at different time points.The time of CTC and carcinoembryonic antigen(CEA) detection is baseline, 2\ 7 days, 3 months, 6 months, 12 months, 24 months, 36 months after the surgery. And the time of CT detection is 6 months, 12 months, 24 months, 36 months after the surgery.
Interventions
None listed
Sponsors
GenoSaber
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Age 18-80 years old * Patients with histologically documented (stage Ⅰ/Ⅱ/ⅢA ) non-small cell lung cancer. * Patients will undergo surgery. * Patients with preoperative CTCs ≥8.5 Units / 3 ml * Informed consent must be obtained from all patients prior to beginning therapy. Patients should have the ability to understand and the willingness to sign a written informed consent document.
Exclusion criteria
* Patients with histologically documented not (stage Ⅰ/Ⅱ/ⅢA ) non-small cell lung cancer. * After the operation review, patients' result of CTC, CT and tumor markers is incomplete at the same point. * The blood sample isn't collected in predetermined time. * The blood samples appear hemolysis. * The blood sample isn't enough.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Circulating tumor cells will be detected by Immunomagnetic negative screening and targeted PCR method. | 3 years |
Secondary
| Measure | Time frame |
|---|---|
| Liconography using conventional CT examination results. | 3 years |
| carcinoembryonic antigen(CEA) concentration will be detected by electrochemical luminescence. | 3 years |
Outcome results
None listed